Company Overview of Glycoregimmune, Inc.
Glycoregimmune, Inc., a development stage biotech company, develops Natural Killer T (NKT) cell-based therapies for liver disease and autoimmunity. Its program includes GRI-0621, an inhibitor of type 1 NKT cells that is developed as an oral therapeutic for liver disease. The company was incorporated in 2009 and is based in San Diego, California.
8954 Rio San Diego Drive
San Diego, CA 92108
Founded in 2009
Key Executives for Glycoregimmune, Inc.
Glycoregimmune, Inc. Key Developments
Similar Private Companies By Industry
|20n Labs, Inc.||United States|
|23andMe, Inc.||United States|
|2C Tech Corporation, Inc.||United States|
|3-V Biosciences, Inc.||United States|
|3D Bio Holdings LLC||United States|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
|Company Name||Geographic Region|
|Lawyers Committee for Civil Rights Under Law||United States|
|Bloomberg L.P.||United States|
|NYC2012, Inc.||United States|
|Rush University||United States|
Sponsored Financial Commentaries
To contact Glycoregimmune, Inc., please visit www.gribio.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.